Caitong International Asset Management Co., LTD Nurix Therapeutics, Inc. Transaction History
Caitong International Asset Management Co., LTD
- $102 Billion
- Q4 2024
A detailed history of Caitong International Asset Management Co., LTD transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Caitong International Asset Management Co., LTD holds 13 shares of NRIX stock, worth $228. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13
Previous 13
-0.0%
Holding current value
$228
Previous $245,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding NRIX
# of Institutions
184Shares Held
70.6MCall Options Held
318KPut Options Held
42.4K-
Black Rock Inc. New York, NY6.82MShares$120 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.35MShares$76.4 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.19MShares$73.7 Million6.18% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$68.3 Million0.81% of portfolio
-
Wellington Management Group LLP Boston, MA3.59MShares$63.1 Million0.01% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $829M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...